Sangamo stock drops 12% premarket on results of phase 1/2 gene editing trial

sangamo stock drops  premarket on results of phase   gene editing trial

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Sangamo stock drops 12% premarket on results of phase 1/2 gene editing trial Sangamo stock drops 12% premarket on results of phase 1/2 gene editing trial Sangamo stock drops 12% premarket on results of phase 1/2 gene editing trial Sangamo stock drops 12% premarket on results of phase 1/2 gene editing trial

Sangamo stock drops 12% premarket on results of phase 1/2 gene editing trial
Read on Market Watch

Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on latest news on stocks, wall street, volatility, news on wall street, articles on investing, trading, options, stocks, futures, #cnbc, #crudeoil, Bitcoin. Hedge Accordingly produces both original, and aggregated Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About HEDGEaccordingly.com